英夫利西单抗联合肠内营养在中重度溃疡性结肠炎治疗中的临床价值

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1360 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：观察英夫利西单抗联合肠内营养（EN）为主的治疗方法对中重度溃疡性结肠炎（UC）患者的临床疗效。方法：收集20例传统治疗无效的中重度UC患者，予英夫利西单抗5 mg/kg的剂量静脉微泵输注一个疗程（共6次）联合EN治疗3个月，并口服硫唑嘌呤进行维持治疗。结果：经治疗后UC患者的BMI、Hb、ALB均较治疗前明显升高（P＜0.05）；UC改良的Mayo评分、CRP、ESR、WBC均较治疗前明显降低（P＜0.05）；16例UC患者治疗有效，其中15例患者达到临床缓解，12患者达到黏膜愈合。随访6～24个月，其中1例患者发生恶性淋巴瘤，1例患者自行停服硫唑嘌呤后病情复发，其余患者病情控制良好未复发。结论：英夫利西单抗联合EN为主诱导UC患者临床缓解、并予硫唑嘌呤维持UC患者临床缓解的方法对于中重度UC患者具有良好的临床疗效，可以改善患者的预后。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邵晓晓
	曹佳乐
	俞玲敏
	蒋益

关键词 ：英夫利西单抗, 肠内营养, 溃疡性结肠炎, 治疗, 硫唑嘌呤

Abstract：Objective: To observe the clinical value of infliximab combined with enteral nutrition (EN) in the treatment of moderate to severe ulcerative colitis (UC). Methods: A total of 20 patients with moderate to severe UC who showed no response to traditional therapies were selected in this study. These UC patients were treated with intravenous micropump of infliximab at a dose of 5 mg/kg for 6 times, combined EN treatment for 3 months and oral azathioprine for maintenance treatment. Results: After treatment, the body mass index (BMI), hemoglobin (Hb) and serum albumin (ALB) in UC patients were all significantly increased than those before treatment (all P<0.05), while the modified Mayo score, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell count (WBC) in UC patients were all lower than those before treatment (all P<0.05). A total of 16 UC patients showed effective response to the treatment, of whom 15 UC patients achieved clinical remission and 12 UC patients achieved mucosal healing. Followed up for 6 to 24 months, 1 UC patient developed malignant lymphoma, 1 UC patient had a relapse after withdrawal of azathioprine, and the remaining patients had good disease control without recurrence. Conclusion: Infliximab combined with EN-induced clinical remission and maintenance therapy with azathioprine could have good clinical efficacy in the treatment of moderate to severe UC, and it also could improve the prognosis of UC patients.

Key words： infliximab enteral nutrition ulcerative colitis treatment azathioprine

收稿日期: 2018-03-03

基金资助:浙江省自然科学基金资助项目（LY14H030012，LY15H030018，LY16H160055，LY17H030011）；温州市科技局科研基金资助项目（Y20170314）。

通讯作者: 蒋益，主任医师，硕士生导师，Email：wzjiangyi@yeah.net。

作者简介: 邵晓晓（1988-），女，浙江温州人，住院医师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I9/684

[1] WANG Y F, OUYANG Q, HU R W. Progression of inflammatory bowel disease in China[J]. J Dig Dis, 2010, 11(2): 76-82.
[2] HIRSCHMANN S, NEURATH M F. Top-down approach to biological therapy of Crohn’s disease[J]. Expert Opin Biol Ther, 2017, 17(3): 285-293.
[3] GROVER Z, MUIR R, LEWINDON P, et al. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease[J]. J Gastroenterol, 2014, 49(4): 638-645.
[4] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年,广州)[J]. 中华消化杂志, 2012, 32(12): 796-813.
[5] XU X R, LIU C Q, FENG B S, et al. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease[J].World J Gastroenterol, 2014, 20(12): 3255-3264.
[6] GROVER Z, MUIR R, LEWINDON P, et al. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease[J]. J Gastroenterol, 2014, 49(4): 638-645.
[7] THANAPATI S, GANU M, GIRI P, et al. Impaired NK cell functionality and increased TNF-α production as biomarkers of chronic chikungunya arthritis and rheumatoid arthritis[J]. Hum Immunol, 2017, 78(4): 370-374.
[8] MOSCA M, TANI C, FILICE M E, et al. TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review[J]. Mod Rheumatol, 2015, 25 (4): 642-645.
[9] CHITUL A, VOIOSU A M, MARINESCU M, et al. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis[J]. Rom J Intern Med, 2017, 55(1): 44-52.
[10] DANESH M J, KOO E B, KIMBALL A B. Effects of TNF-alpha antagonism in patients with metabolic syndrome and psoriasis[J]. J Eur Acad Dermatol Venereol, 2016, 30(11): e152-e154.
[11] MARINI J C, SENDECKI J, CORNILLIE F, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®[J]. AAPS J, 2017, 19(1): 161-171.
[12] RUTGEERTS P, VERMEIRE S, VAN ASSCHE G. Biological therapies for inflammatory bowel diseases[J]. Gastroenterology, 2009, 136: 1182-1197.
[13] COTTONE M, MOCCIARO F, ORLANDO A. Infliximab prevents Crohn’s disease recurrence after ileal resection[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(3): 231-234.
[14] FIORINO G, BONOVAS S, CICERONE C, et al. The safety of biological pharmacotherapy for the treatment of ulcerative colitis[J]. Expert Opin Drug Saf, 2017, 16(4): 437-443.
[15] 李世荣, 陆晓娟, 盛剑秋, 等. 溃疡性结肠炎和克罗恩的英夫利西(类克)治疗效果比较[J]. 胃肠病学和肝病学杂志, 2010, 19(7): 644-647.
[16] RADIN M, SCIASCIA S, ROCCATELLO D, et al. Infliximab biosimilars in the treatment of inflammatory bowel diseases: A systematic review[J]. Bio Drugs, 2017, 31(1): 37-49.
[17] ALTOMARE R, DAMIANO G, ABRUZZO A, et al. Enteral nutrition support to treat malnutrition in inflammatory bowel disease[J]. Nutrients, 2015, 7(4): 2125-2133.